Peng Wang, Bangping Cui, Wenli Dai, Pengyi Deng, Jinling Tian, Wei Hu. Progress in the application of 18F-FDG PET/CT in prostate cancer[J]. Int J Radiat Med Nucl Med, 2016, 40(4): 277-281. DOI: 10.3760/cma.j.issn.1673-4114.2016.04.008
Citation: Peng Wang, Bangping Cui, Wenli Dai, Pengyi Deng, Jinling Tian, Wei Hu. Progress in the application of 18F-FDG PET/CT in prostate cancer[J]. Int J Radiat Med Nucl Med, 2016, 40(4): 277-281. DOI: 10.3760/cma.j.issn.1673-4114.2016.04.008

Progress in the application of 18F-FDG PET/CT in prostate cancer

  • Prostate cancer has become one of the most common clinical malignant tumors worldwide, and the incidence of prostate cancer in our country is rising. 18F-FDG is a broad-spectrum nonspecific tumor imaging agent with important value in numerous tumors. According to clinical practice, the value of 18F-FDG PET/CT imaging in the diagnosis of early prostate is limited. Recent studies found that 18F-FDG PET/CT is still crucial in the clinical staging, curative effect evaluation, and prognostic evaluation of prostate cancer. This paper mainly introduces the application and progress of PET/CT in prostate cancer.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return